SCHEMBL1246697

SCHEMBL1246697

COc1ccc(C(=O)Cc2ccccc2OC)c(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.65
NPC1 O15118 5/20 0.65
ALDH1A1 P00352 3/20 0.65
PKM P14618 2/20 0.65
HTT P42858 2/20 0.65
GAA P10253 1/20 0.65
HPGD P15428 1/20 0.65
SMN1; SMN2 Q16637 3/20 0.64
TTR P02766 1/20 0.64
LMNA P02545 1/20 0.62
L3MBTL1 Q9Y468 4/20 0.55
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.55
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16324582 0.88 TTR (0.60) RAB9ANPC1ALDH1A1PKMHTT
SCHEMBL332837 0.84 TTR (0.66) NPC1ALDH1A1HTTHPGDSMN1; SMN2
SCHEMBL224315 0.80 NPC1 (0.83) RAB9ANPC1ALDH1A1PKMHTT
SCHEMBL31040323 0.80 L3MBTL1 (0.72) RAB9ANPC1HTTHPGDSMN1; SMN2
SCHEMBL9057785 0.80 L3MBTL1 (0.72) RAB9ANPC1HTTHPGDSMN1; SMN2
SCHEMBL2978070 0.79 SMN1; SMN2 (0.65) RAB9ANPC1ALDH1A1PKMHTT
SCHEMBL7188085 0.78 PKM (0.64) RAB9ANPC1ALDH1A1PKMHTT
SCHEMBL236515 0.78 TTR (1.00) RAB9ANPC1ALDH1A1HTTHPGD
SCHEMBL22362720 0.78 MAPT (0.59) RAB9ANPC1ALDH1A1PKMHTT
SCHEMBL5914630 0.78 SMN1; SMN2 (0.63) RAB9ANPC1ALDH1A1PKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295031-B1 Use of pterocarpans as anti-cellulite agents SYMRISE AG (DE) 2018-01-10 EP disclosed
US-8633203-B2 Use of pterocarpans as active anti-cellulite ingredients SYMRISE AG (DE) 2014-01-21 US disclosed
US-8633203-B2 Use of pterocarpans as active anti-cellulite ingredients SYMRISE AG (DE) 2014-01-21 US disclosed
US-8633203-B2 Use of pterocarpans as active anti-cellulite ingredients SYMRISE AG (DE) 2014-01-21 US disclosed
EP-2295031-A2 Use of pterocarpans as anti-cellulite agents Symrise AG (DE) 2011-03-16 EP disclosed
EP-2295031-A2 Use of pterocarpans as anti-cellulite agents Symrise AG (DE) 2011-03-16 EP disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 US disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 US disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS FABP4, PLIN1, CPT1B RAB9A 2006/4885NPC1 1513/4885ALDH1A1 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.